Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158497 | 0.93 | TSHR (0.55) | TSHRALDH1A1SMN1; SMN2POLBHTT | |
| Hydrochloric Acid SCHEMBL27776511 | 0.91 | TSHR (0.53) | TSHRALDH1A1SMN1; SMN2POLBHTT | |
| SCHEMBL6306521 | 0.86 | TSHR (0.44) | TSHRALDH1A1SMN1; SMN2POLBHTT | |
| SCHEMBL861719 | 0.85 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2POLBMAPTTDP1 | |
| SCHEMBL4077922 | 0.83 | MEN1 (0.44) | TDP1LMNAMEN1KMT2A | |
| SCHEMBL12658314 | 0.83 | MAPT (0.39) | TSHRALDH1A1GAAMAPTLMNA | |
| SCHEMBL568818 | 0.81 | TSHR (0.47) | TSHRALDH1A1SMN1; SMN2POLBHTT | |
| SCHEMBL27350623 | 0.81 | CYP1A2 (0.40) | TSHRALDH1A1SMN1; SMN2POLBMAPT | |
| SCHEMBL11072823 | 0.81 | TSHR (0.55) | TSHRALDH1A1SMN1; SMN2POLBHTT | |
| SCHEMBL2223429 | 0.80 | TSHR (0.63) | TSHRALDH1A1SMN1; SMN2POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| EP-3638658-B1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-10-08 | — | — | EP | disclosed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-12291512-B2 | Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor | NXERA PHARMA UK LIMITED (GB) | 2025-05-06 | — | — | US | disclosed |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| WO-2024168426-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-08-22 | — | — | WO | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20220298133-A1 | OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| US-4814450-A | CENTRAL NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0297661-A1 | [(Bicyclic heterocyclyl)methyl and -hetero] substituted hexahydro-1H-azepines and pyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-04 | — | — | EP | disclosed |
| EP-0282133-A2 | 1-alkyl substituted benzimidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-09-14 | — | — | EP | disclosed |
| US-4740512-A | Treating anxiety with certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives | CIBA-GEIGY CORPORATION (US) | 1988-04-26 | — | — | US | disclosed |
| US-4647566-A | Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives in treating anxiety | CIBA-GEIGY CORPORATION (US) | 1987-03-03 | — | — | US | disclosed |
| US-4602014-A | NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1986-07-22 | — | — | US | disclosed |
| EP-0168350-A2 | Certain ring-fused pyrazolo [3,4-d]-pyridin-3-one derivatives | CIBA-GEIGY AG (CH) | 1986-01-15 | — | — | EP | disclosed |
| US-4486433-A | SLOWING HEART RATE | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-12-04 | — | — | US | disclosed |
| US-4409220-A | Fused-ring amino-pyrazines as bradycardiac agents | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-10-11 | — | — | US | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291512-B2 | Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor | CHRM1, CHRM2, CHRM4 | TSHR 52/4885ALDH1A1 1895/4885SMN1; SMN2 2064/4885 |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | MGLL, PNLIP, LPL | TSHR 4582/4885ALDH1A1 530/4885SMN1; SMN2 502/4885 |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | MGLL, PNLIP, LPL | TSHR 4582/4885ALDH1A1 530/4885SMN1; SMN2 502/4885 |
| US-20220298133-A1 | OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | TSHR 55/4885ALDH1A1 1559/4885SMN1; SMN2 1953/4885 |
| US-11793817-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | TSHR 101/4885ALDH1A1 1394/4885SMN1; SMN2 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.